156 related articles for article (PubMed ID: 38238578)
1. Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017.
Reitmajer M; Leiter U; Nanz L; Amaral T; Flatz L; Garbe C; Forschner A
J Cancer Res Clin Oncol; 2024 Jan; 150(1):15. PubMed ID: 38238578
[TBL] [Abstract][Full Text] [Related]
2. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors.
Lai-Kwon J; Khoo C; Lo S; Milne D; Mohamed M; Raleigh J; Smith K; Lisy K; Sandhu S; Jefford M
J Cancer Surviv; 2019 Aug; 13(4):503-511. PubMed ID: 31165342
[TBL] [Abstract][Full Text] [Related]
3. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
4. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
5. [Locally recurrent and metastatic malignant melanoma. Long-term results and prognostic factors after percutaneous radiotherapy].
Seegenschmiedt MH; Keilholz L; Pieritz A; Altendorf-Hofmann A; Urban A; Schell H; Hohenberger W; Sauer R
Strahlenther Onkol; 1999 Sep; 175(9):450-7. PubMed ID: 10518979
[TBL] [Abstract][Full Text] [Related]
6. Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.
Soerensen AV; Ellebaek E; Bastholt L; Schmidt H; Donia M; Svane IM
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32932758
[TBL] [Abstract][Full Text] [Related]
7. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Forschner A; Eichner F; Amaral T; Keim U; Garbe C; Eigentler TK
J Cancer Res Clin Oncol; 2017 Mar; 143(3):533-540. PubMed ID: 27878363
[TBL] [Abstract][Full Text] [Related]
8. Long-term survivors in stage IV melanoma: a regional population-based study in France.
Tchen T; Léonard F; Derancourt C; Perceau G; Goutorbe C; Reguiaï Z; Bernard P; Grange F
Eur J Dermatol; 2009; 19(1):38-43. PubMed ID: 19059830
[TBL] [Abstract][Full Text] [Related]
9. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review.
Lai-Kwon J; Inderjeeth AJ; Lisy K; Sandhu S; Rutherford C; Jefford M
Eur J Cancer; 2023 May; 184():83-105. PubMed ID: 36907021
[TBL] [Abstract][Full Text] [Related]
10. "How Long Have I Got?" in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question.
Guo H; Li H; Zhu L; Feng J; Huang X; Baak JPA
Front Oncol; 2021; 11():761042. PubMed ID: 34993132
[TBL] [Abstract][Full Text] [Related]
11. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.
Seegenschmiedt MH; Keilholz L; Altendorf-Hofmann A; Urban A; Schell H; Hohenberger W; Sauer R
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):607-18. PubMed ID: 10348291
[TBL] [Abstract][Full Text] [Related]
12. Treatment management for
Haist M; Stege H; Rogall F; Tan Y; von Wasielewski I; Klespe KC; Meier F; Mohr P; Kähler KC; Weichenthal M; Hauschild A; Schadendorf D; Ugurel S; Lodde G; Zimmer L; Gutzmer R; Debus D; Schilling B; Kreuter A; Ulrich J; Meiss F; Herbst R; Forschner A; Leiter U; Pfoehler C; Kaatz M; Ziller F; Hassel JC; Tronnier M; Sachse M; Dippel E; Terheyden P; Berking C; Heppt MV; Kiecker F; Haferkamp S; Gebhardt C; Simon JC; Grabbe S; Loquai C
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730278
[TBL] [Abstract][Full Text] [Related]
13. Use of immunotherapy and surgery for stage IV melanoma.
Molina G; Kasumova GG; Qadan M; Boland GM
Cancer; 2020 Jun; 126(11):2614-2624. PubMed ID: 32157676
[TBL] [Abstract][Full Text] [Related]
14. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
[TBL] [Abstract][Full Text] [Related]
15. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.
Keilholz U; Martus P; Punt CJ; Kruit W; Mooser G; Schadendorf D; Liénard D; Dummer R; Koller J; Voit C; Eggermont AM
Eur J Cancer; 2002 Jul; 38(11):1501-11. PubMed ID: 12110497
[TBL] [Abstract][Full Text] [Related]
17. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors.
Brand CU; Ellwanger U; Stroebel W; Meier F; Schlagenhauff B; Rassner G; Garbe C
Cancer; 1997 Jun; 79(12):2345-53. PubMed ID: 9191522
[TBL] [Abstract][Full Text] [Related]
18. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
Versluis JM; Hendriks AM; Weppler AM; Brown LJ; de Joode K; Suijkerbuijk KPM; Zimmer L; Kapiteijn EW; Allayous C; Johnson DB; Hepner A; Mangana J; Bhave P; Jansen YJL; Trojaniello C; Atkinson V; Storey L; Lorigan P; Ascierto PA; Neyns B; Haydon A; Menzies AM; Long GV; Lebbe C; van der Veldt AAM; Carlino MS; Sandhu S; van Tinteren H; de Vries EGE; Blank CU; Jalving M
Eur J Cancer; 2021 Jul; 151():72-83. PubMed ID: 33971447
[TBL] [Abstract][Full Text] [Related]
19. Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Mangana J; Cheng PF; Kaufmann C; Amann VC; Frauchiger AL; Stögner V; Held U; von Moos R; Michielin O; Braun RP; Levesque MP; Goldinger SM; Dummer R
Melanoma Res; 2017 Aug; 27(4):358-368. PubMed ID: 28509765
[TBL] [Abstract][Full Text] [Related]
20. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
Lodde GC; Jansen P; Möller I; Sucker A; Hassel JC; Forschner A; Eckardt J; Meier F; Reinhardt L; Kähler KC; Ziemer M; Schlaak M; Rahimi F; Schatton K; Meiss F; Gutzmer R; Pföhler C; Terheyden P; Schilling B; Sachse M; Heppt MV; Sindrilaru A; Leiter U; Zaremba A; Thielmann CM; Ugurel S; Zimmer L; Hadaschik E; Bechrakis NE; Schadendorf D; Westekemper H; Livingstone E; Griewank KG;
Eur J Cancer; 2022 May; 166():60-72. PubMed ID: 35279471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
